The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
21h
Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) had its price objective lowered by JPMorgan Chase & Co. from $47.00 to $45.00 in a research report released on Monday,Benzinga reports. JPMorgan Chase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback